Bruker(BRKR)

Search documents
Seattle biotech company NanoString to be acquired by Bruker for $392M, ending bankruptcy process
GeekWire· 2024-04-18 01:05
NanoString’s GeoMX Digital Spatial Profiler was at the heart of a patent lawsuit filed by 10x Genomics. (NanoString Image)NanoString announced Wednesday that it will be acquired by Bruker, ending the company’s restructuring process that included a Chapter 11 bankruptcy plan. Bruker, a Massachusetts-based publicly traded life sciences research and diagnostic giant founded in 1960, will pay $392.6 million to buy Seattle-based NanoString. The deal is expected to close next month. NanoString said in February th ...
Bruker (BRKR) Introduces Magnet Technology for NMR Adoption
Zacks Investment Research· 2024-04-09 14:06
Bruker Corporation (BRKR) introduced novel magnet technology and analytical solutions at the 65th ENC. The novel technology facilitates the widespread application of NMR in academic basic and clinical research, as well as in drug discovery and development by biopharmacies and process analytical technologies (PAT).The latest development will fortify Bruker’s Scientific Instruments (BSI) BioSpin segment.More on New Magnet TechnologyAt the 65th ENC, with a complete one-year liquid helium hold-time, more than d ...
Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
Prnewswire· 2024-04-04 12:11
In the Industry Spotlight Theater session hosted by Alamar at the American Society for Cancer Research (AACR) 2024 Annual Meeting in San Diego on April 9 at 12:30 pm PT, the companies will jointly present data from a collaborative study focused on Non-Small Cell Lung Cancer (NSCLC). In this study, plasma samples from a cohort of NSCLC patients were analyzed using both the Biognosys TrueDiscovery® unbiased discovery platform and Alamar's NULISAseq™ Inflammation Panel 250. The findings demonstrate the feasibi ...
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
Zacks Investment Research· 2024-03-22 14:51
Shares of Bruker Corporation (BRKR) reached a new 52-week high of $94.86 on Mar 21 before closing the session marginally lower at $94.27.In the past year, this Zacks Rank #3 (Hold) stock has risen 25.9% against a 1.1% decline of the industry and the S&P 500 composite’s rise of 32.2%.Over the past five years, Bruker registered earnings growth of 13%, comparing favorably with the industry’s 5.1% rise. The company has an expected long-term earnings growth rate of 14.4%. Bruker’s earnings surpassed the Zacks Co ...
PharmaVentures acts as the exclusive M&A advisor on the successful sale of Phasefocus to Bruker
Prnewswire· 2024-03-19 09:00
LONDON, March 19, 2024 /PRNewswire/ -- PharmaVentures is pleased to announce that it acted as the exclusive advisor to Phasefocus Holdings Limited on its sale to Bruker (NASDAQGS:BRKR). Phasefocus is a privately held company that has leading expertise in imaging, image processing algorithms and imaging platform. Phasefocus has deployed their expertise to develop a novel optical microscope, called Livecyte, for label-free cell imaging. Phasefocus' microscopy capabilities will enhance Bruker's existing portfo ...
Why Is Bruker (BRKR) Up 15.7% Since Last Earnings Report?
Zacks Investment Research· 2024-03-14 16:36
It has been about a month since the last earnings report for Bruker (BRKR) . Shares have added about 15.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Bruker Q4 Earnings Top Estimates, Margins FallBruker Cor ...
Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?
Zacks Investment Research· 2024-03-14 14:10
Bruker Corporation (BRKR) appears in good shape, with its shares rising 20.7% since the fourth-quarter earnings release. The company continues to benefit from its innovative, high-performance product lines. The AI-driven semiconductor and advanced packaging metrology tools in the NANO group are performing well.The Zacks Rank #2 (Buy) stock has increased 20.7% since the last earnings release compared with the industry’s rise of 15%. The Medical sector has gained 3.6% in the said time frame. The company has a ...
Bruker (BRKR) Announces Advanced timsTOF Solutions at US HUPO
Zacks Investment Research· 2024-03-12 12:55
Bruker Corporation (BRKR) recently announced its progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows at the 20th US Human Proteome Organization Congress 2024. The advances include improved machine-learning de novo sequencing (Novor V2.0), a novel high-performance monitoring digital-twin software (TwinScape), the new glyco-PASEF method for high-sensitivity glycopeptide analysis and access to Spectronaut 18 for users of Bruker ProteoScape — a GPU-powered software for r ...
Bruker Announces Closing of Chemspeed Technologies AG Acquisition
Businesswire· 2024-03-07 12:00
BASEL, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider of automated laboratory R&D and QC workflow solutions. This acquisition, first announced in January 2024, marks another significant milestone in Bruker’s expansion in vendor-agnostic scientific software, R&D and QC digitalization, and laboratory automation – altogether an important initiative within Bruker’s strategic P ...
Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup
Zacks Investment Research· 2024-03-01 14:41
Bruker Corporation (BRKR) recently entered into a definitive share purchase agreement with TecFin S.à r.l., a controlled affiliate of the pre-eminent private equity firm PAI Partners, to acquire ELITechGroup. However, the €870 million cash transaction excludes the carved-out ELITech clinical chemistry business.The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals, the carve-out of the clinical chemistry business and other customary closing conditions. Upon closi ...